Covaxin is the first 100% Indian vaccine, developed by the biotechnology company Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Virology Institute. This vaccine is based on an inactive virus. It uses a non-infectious variant of the virus causing the disease, which is unable to infect but able to trigger an immune response.
The clinical trials started in July 2020 and the results were published on the 3rd of March 2021. A total of 25,800 people participated in phase III trials, with results showing an 81% of efficacy.
Covaxin consists of 2-dose series separated by 28 days and almost ten countries in Asia are using this vaccine to immunise their population.
The most reported side effects, according to Bharar Biotech, are pain, inflammation or redness at the vaccination site, itching, rashes, headache, fever, body discomfort, nausea, and vomit. Severe allergic reactions may occur on very rare occasions, according to the company.
Covaxin is stored at an average temperature between 2ºC and 8ºC.
We are a team of young journalists from Barcelona who work independently to combat misinformation in our territory and beyond. We rely on facts and data to verify what politicians say and the falsehoods circulating on social media.
We need you. With your contribution, you will contribute to a healthier political debate and help promote educational projects to teach citizens how to navigate information chaos and defend themselves against misinformation.
You can contribute as much as one euro and it won't take you more than 45 seconds (we've counted them). If you can, please mark your contribution as monthly and so we can continue to do our job rigorously and independently. Thank you so much.
Donate